BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 11053905)

  • 1. In vitro susceptibility of Candida dubliniensis to current and new antifungal agents.
    Quindós G; Carrillo-Muñoz AJ; Arévalo MP; Salgado J; Alonso-Vargas R; Rodrigo JM; Ruesga MT; Valverde A; Pemán J; Cantón E; Martín-Mazuelos E; Pontón J
    Chemotherapy; 2000; 46(6):395-401. PubMed ID: 11053905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.
    Pfaller MA; Messer SA; Gee S; Joly S; Pujol C; Sullivan DJ; Coleman DC; Soll DR
    J Clin Microbiol; 1999 Mar; 37(3):870-2. PubMed ID: 9986880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species.
    Moore CB; Oakley KL; Denning DW
    Clin Microbiol Infect; 2001 Jan; 7(1):11-6. PubMed ID: 11284937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro efficacy of amphotericin B, 5-fluorocytosine, fluconazole, voriconazole and posaconazole against Candida dubliniensis isolates using time-kill methodology.
    Szabo Z; Borbely A; Kardos G; Somogyvari F; Kemény-Beke A; Asztalos L; Rozgonyi F; Majoros L
    Mycoses; 2010 May; 53(3):196-9. PubMed ID: 19761489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro susceptibility of oral Candida to seven antifungal agents.
    Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
    Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro.
    Moran GP; Sullivan DJ; Henman MC; McCreary CE; Harrington BJ; Shanley DB; Coleman DC
    Antimicrob Agents Chemother; 1997 Mar; 41(3):617-23. PubMed ID: 9056003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro susceptibility of 245 yeast isolates to amphotericin B, 5-fluorocytosine, ketoconazole, fluconazole and itraconazole.
    Martín E; Parras P; Lozano MC
    Chemotherapy; 1992; 38(5):335-9. PubMed ID: 1337508
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    O'Brien B; Chaturvedi S; Chaturvedi V
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B.
    Cuenca-Estrella M; Mellado E; Díaz-Guerra TM; Monzón A; Rodríguez-Tudela JL
    J Antimicrob Chemother; 2000 Sep; 46(3):475-7. PubMed ID: 10980178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.
    Marco F; Pfaller MA; Messer S; Jones RN
    Antimicrob Agents Chemother; 1998 Jan; 42(1):161-3. PubMed ID: 9449278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey.
    Dagi HT; Findik D; Senkeles C; Arslan U
    Ann Clin Microbiol Antimicrob; 2016 May; 15(1):36. PubMed ID: 27245756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance Surveillance in Candida albicans: A Five-Year Antifungal Susceptibility Evaluation in a Brazilian University Hospital.
    Peron IH; Reichert-Lima F; Busso-Lopes AF; Nagasako CK; Lyra L; Moretti ML; Schreiber AZ
    PLoS One; 2016; 11(7):e0158126. PubMed ID: 27414653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
    Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents.
    Pfaller MA; Diekema DJ; Messer SA; Boyken L; Hollis RJ; Jones RN
    Diagn Microbiol Infect Dis; 2004 Feb; 48(2):101-5. PubMed ID: 14972378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimum inhibitory concentrations of amphotericin B, azoles and caspofungin against Candida species are reduced by farnesol.
    Cordeiro RA; Teixeira CE; Brilhante RS; Castelo-Branco DS; Paiva MA; Giffoni Leite JJ; Lima DT; Monteiro AJ; Sidrim JJ; Rocha MF
    Med Mycol; 2013 Jan; 51(1):53-9. PubMed ID: 22712455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In vitro activity of voriconazole and other antifungal agents against clinical isolates of 138 Candida spp].
    Ricciardi AM; Ricciardi R; Danzi M; Mungiguerra M; Pisano L; Marino A
    Infez Med; 2009 Mar; 17(1):24-7. PubMed ID: 19359821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro susceptibility of Candida albicans clinical isolates to eight antifungal agents in Ouagadougou (Burkina Faso).
    Zida A; Yacouba A; Bamba S; Sangare I; Sawadogo M; Guiguemde T; Kone S; Traore LK; Ouedraogo-Traore R; Guiguemde RT
    J Mycol Med; 2017 Dec; 27(4):469-475. PubMed ID: 28754462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts.
    Park BJ; Park JC; Taguchi H; Fukushima K; Hyon SH; Takatori K
    Biochem Biophys Res Commun; 2006 Aug; 347(2):401-5. PubMed ID: 16831406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
    Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
    J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and antifungal susceptibility of Candida parapsilosis complex isolates collected from oral cavities of HIV-infected individuals.
    Moris DV; Melhem MSC; Martins MA; Souza LR; Kacew S; Szeszs MW; Carvalho LR; Pimenta-Rodrigues MV; Berghs HAM; Mendes RP
    J Med Microbiol; 2012 Dec; 61(Pt 12):1758-1765. PubMed ID: 22956748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.